{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:22:23Z","timestamp":1793046143749,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jacc.2023.10.045","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T14:00:02Z","timestamp":1705932002000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Randomized Trial of Macitentan\/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"83","author":[{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Pannaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Rofael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.10.045_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th World Symposium on Pulmonary Hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2023.10.045_bib2","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.10.045_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2023.10.045_bib4","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.10.045_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.10.045_bib6","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1183\/13993003.02043-2015","article-title":"Initial dual oral combination therapy in pulmonary arterial hypertension","volume":"47","author":"Sitbon","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2023.10.045_bib7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1183\/16000617.0085-2016","article-title":"Beyond a single pathway: combination therapy in pulmonary arterial hypertension","volume":"25","author":"Sitbon","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jacc.2023.10.045_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40256-017-0260-1","article-title":"Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the SERAPHIN trial","volume":"18","author":"Jansa","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2023.10.045_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00673-2020","article-title":"Initial combination therapy with macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension: Results from the OPTIMA trial","volume":"56","author":"Sitbon","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2023.10.045_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.10.045_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1183\/23120541.00299-2020","article-title":"Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension","volume":"6","author":"Kjellstr\u00f6m","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jacc.2023.10.045_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2023.10.045_bib13","first-page":"115","article-title":"One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects","volume":"4","author":"Airoldi","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jacc.2023.10.045_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacc.2023.10.045_bib15","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/bcp.14347","article-title":"Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects","volume":"86","author":"Grill","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2023.10.045_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.846","article-title":"Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic","volume":"9","author":"Csonka","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jacc.2023.10.045_bib19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/sim.4780091207","article-title":"Group sequential designs using a family of type I error probability spending functions","volume":"9","author":"Hwang","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2023.10.045_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02024-2021","article-title":"Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry","volume":"59","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2023.10.045_bib21","doi-asserted-by":"crossref","first-page":"2101552","DOI":"10.1183\/13993003.01552-2021","article-title":"Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC\/ERS guideline era","volume":"59","author":"Zelt","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2023.10.045_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/2045893217743616","article-title":"Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies","volume":"8","author":"Grady","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jacc.2023.10.045_bib23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","article-title":"Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension","volume":"157","author":"D\u2019Alto","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2023.10.045_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002054","article-title":"Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension","volume":"9","author":"Suzuki","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.jacc.2023.10.045_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1086\/674338","article-title":"Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension","volume":"3","author":"Tiede","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jacc.2023.10.045_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972308138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972308138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:30:22Z","timestamp":1724963422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972308138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S073510972308138X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.10.045","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Trial of Macitentan\/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.10.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}